GS UHL (Votrient pazopanib 400 mg)
Generic Name: pazopanib
Pill with imprint GS UHL is Yellow, Capsule-shape and has been identified as Votrient pazopanib 400 mg. It is supplied by GlaxoSmithKline.
Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 400 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS UHL
Votrient
- Generic Name:
- pazopanib
- Imprint:
- GS UHL
- Strength:
- pazopanib 400 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- VEGF/VEGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- GlaxoSmithKline
- National Drug Code (NDC):
More about Votrient (pazopanib)
- Votrient Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 64 Reviews
- Drug class: VEGF/VEGFR inhibitors
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
